Silexion Therapeutics Announces It Will Appeal Nasdaq Delisting Notice

On May 28, 2025,  Silexion Therapeutics Corp, a Cayman Islands exempted company (the "Company", "we", "us" or "our") requested a hearing related to the delisting notice that the Company had received from the Nasdaq Listing Qualifications Department on May 22, 2025 in respect of two listing deficiencies. As a result of our hearing  request, the delisting process in respect of the Company's ordinary shares and warrants has been stayed, at least until the date of the hearing, and our securities will therefore continue trading on the Nasdaq Global Market under the existing symbols "SLXN" and "SLXNW", respectively.

As we had previously reported (initially under "Market Value-Related Deficiencies" in Item 3.01 of our Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on November 22, 2024), the two listing deficiencies, for which we had received two letters from the Nasdaq Listing Qualifications Department on November 19, 2024, relate to our non-compliance with Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C), which require a company such as ours whose securities are listed on the Nasdaq Global Market under the "Market Value Standard" to maintain a minimum Market Value of Listed Securities (an "MVLS") of $50,000,000 and a minimum Market Value of Publicly Held Shares (an "MVPHS") of $15,000,000 for continued listing on the Nasdaq Global Market. Under Nasdaq Listing Rule 5810(c)(3)(C), we had been given a 180-day period, ending on May 19, 2025, to rectify the deficiencies, but were unable to do so during that period.

As also previously disclosed in our Current Report on Form 8-K filed with the SEC on May 23, 2025, as part of our strategy for our appeal, we intend to apply to transfer the listing of our securities to the Nasdaq Capital Market, subject to our meeting the Equity Standard for continued listing on that market, which requires us to have, among other things, at least $2.5 million of shareholders' equity. We may also request from the Nasdaq Hearings Panel additional time to meet that Equity Standard. There can be no assurance, however, that our hearing and request for transfer will be successful or that we will successfully comply with that Equity Standard for listing on the Nasdaq Capital Market within any extension period that may be granted by the Nasdaq Hearings Panel.